Frank Rimerman Advisors LLC Makes New Investment in Axon Enterprise, Inc. (NASDAQ:AXON)

Frank Rimerman Advisors LLC purchased a new position in shares of Axon Enterprise, Inc. (NASDAQ:AXON) in the fourth quarter, Holdings Channel reports. The fund purchased 481 shares of the biotechnology company’s stock, valued at approximately $286,000.

Other institutional investors also recently added to or reduced their stakes in the company. Public Sector Pension Investment Board boosted its position in Axon Enterprise by 19.2% during the 3rd quarter. Public Sector Pension Investment Board now owns 3,104 shares of the biotechnology company’s stock worth $1,240,000 after acquiring an additional 500 shares during the period. CIBC Asset Management Inc boosted its position in Axon Enterprise by 9.2% during the 3rd quarter. CIBC Asset Management Inc now owns 10,578 shares of the biotechnology company’s stock worth $4,227,000 after acquiring an additional 895 shares during the period. Soros Capital Management LLC acquired a new position in Axon Enterprise during the 3rd quarter worth $630,000. Friedenthal Financial boosted its position in Axon Enterprise by 961.7% during the 4th quarter. Friedenthal Financial now owns 1,359 shares of the biotechnology company’s stock worth $808,000 after acquiring an additional 1,231 shares during the period. Finally, Principal Financial Group Inc. boosted its position in Axon Enterprise by 33.1% during the 3rd quarter. Principal Financial Group Inc. now owns 136,302 shares of the biotechnology company’s stock worth $54,466,000 after acquiring an additional 33,869 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Trading Down 0.3 %

Shares of NASDAQ AXON opened at $554.82 on Tuesday. Axon Enterprise, Inc. has a 12 month low of $273.52 and a 12 month high of $715.99. The company has a market cap of $42.51 billion, a price-to-earnings ratio of 143.36, a P/E/G ratio of 5.17 and a beta of 1.12. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The business has a fifty day simple moving average of $593.10 and a 200-day simple moving average of $538.04.

Insider Buying and Selling

In related news, insider Jeffrey C. Kunins sold 1,035 shares of the stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $624.47, for a total value of $646,326.45. Following the completion of the sale, the insider now directly owns 124,243 shares of the company’s stock, valued at approximately $77,586,026.21. This represents a 0.83 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total value of $271,831.50. Following the completion of the sale, the director now directly owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. This represents a 6.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 6.10% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. JMP Securities reissued an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. Robert W. Baird boosted their price objective on Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research note on Friday, December 6th. Northcoast Research downgraded Axon Enterprise from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 19th. The Goldman Sachs Group boosted their price objective on Axon Enterprise from $500.00 to $700.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $600.00 price objective on shares of Axon Enterprise in a research note on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $604.67.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.